Outlook Therapeutics (OTLK) to Release Quarterly Earnings on Thursday

Outlook Therapeutics (NASDAQ:OTLK) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 16th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.20. On average, analysts expect Outlook Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Outlook Therapeutics Stock Down 3.4 %

Shares of OTLK opened at $7.73 on Friday. The stock has a fifty day simple moving average of $8.50 and a two-hundred day simple moving average of $8.58. The company has a market capitalization of $100.59 million, a PE ratio of -1.93 and a beta of 0.28. Outlook Therapeutics has a 52-week low of $4.00 and a 52-week high of $40.60.

Analysts Set New Price Targets

Several equities analysts have weighed in on OTLK shares. HC Wainwright boosted their target price on shares of Outlook Therapeutics to $30.00 and gave the company a “buy” rating in a report on Monday, March 25th. Capital One Financial reissued an “overweight” rating on shares of Outlook Therapeutics in a research note on Friday, February 16th. BTIG Research raised Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $50.00 price target on the stock in a research note on Wednesday, March 27th. Chardan Capital raised Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $60.00 price objective for the company in a research report on Thursday, February 15th. Finally, Guggenheim raised shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $40.00 target price on the stock in a research report on Thursday, January 25th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.43.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.